Jindike Shares Plunge as Approved Flu Vaccine Faces Sales Delay and Delisting Risk
Approval does not equal availability; batch release delays cause Jindike to miss the flu season sales window, triggering revenue collapse and delisting warnings.
ImportanceMaterialEvidenceE3 inspectableWrite-upStandard
Jindike (688670.SH) shares fell 19.98% to close at 15.34 yuan on October 12, despite the recent approval of its trivalent influenza vaccine.
The decline stems from a regulatory bottleneck: while the product is approved, it requires up to 45 days for batch release before it can be sold. Influenza vaccines have a strict seasonal sales window from September to December, meaning any delay results in a complete loss of annual revenue potential.
Financial data highlights the severity: Jindike's revenue for the first half of 2026 was only 910,000 yuan, compared to 113 million yuan for all of 2025. The company warned that full-year revenue may fall below 100 million yuan with no profit turnaround, potentially triggering financial delisting risk warnings.
This case illustrates a specific investment risk in biopharma: for small-cap companies dependent on single seasonal products, the time lag between approval and market availability can threaten survival rather than just impact quarterly earnings.